b'AVAILABLESOON: Quality Projects: UpdateNew MOQCMOQC practices can take part in several MOQC quality improvement projects, some of which are Maintenance-of-Certification (MOC) eligible. Be sure to visit moqc.org Measures for for the most up-to-date information on each initiative.YOURPATIENTSONHOSPICECANNOWACCESSPALLIATIVERADIATIONTHERAPYFORBONEPAINATSELECTRADIATIONONCOLOGYPRACTICESAROUNDTHESTATECollaboration between medical oncology, radiation oncology, and hospice providers across Michigan provides a unique opportunity to improve the quality of care for oncology patients in hospice. To date, radiation oncologists at 18 practices as well as The MOQC Measures Committee met8 hospices around the state have signed up to participate in the first Bony Metastases in September and reviewed theTreatment Pathway. Further outreach to both radiation oncologists and leaders at current measures as well as allMichigan hospices is ongoing. A map with each participating radiation oncology available measures in the ASCO QOPIcenter and hospice is available under Initiatives on the MOQC website moqc.org platform. All members of the PatientThe Working Group also created a patient guide, Palliative and Caregiver Oncology QualityRadiation Treatment: What to Expect that explains what will Counsel (POQC) were invited.happen if they are referred. If you want more hospice The updated measures are schedulededucational materials that were created for you, visit the for review by the MOQC SteeringMOQC website for our Hospice Toolkit at moqc.org.Committee in November. We will postAll toolkit materials can be self-printed, or you can email a them on the website and email all ofrequest to have the materials printed by MOQC with your you as soon as they have beenpractices logo.approved.Centering patients and caregivers isFinally, the Working Group, which includes radiation the principle criterion for measuresoncologists, medical oncologists, and hospice directors, will selection. The other criteria are thatfocus next on creating a Bleeding Treatment Pathway. the measures must be related to aReach out to SamBeusterien at sbeusterien@moqc.org if meaningful outcome, mustyou have an interest in serving on the working group to incorporate attention to the impactdevelop our next protocol.on equity, need to reflect a gap inOPPORTUNITY:BRINGAMBULATORYCLINICALONCOLOGYPHARMACISTScare, and must be feasible to measureINTOYOURPRACTICETOPROVIDECARETOHIGH-RISKPATIENTS.& improve. Measures that includePharmacists Optimizing Oncology Care Excellence in Michigan (POEM) is a collaboration only a small number of patients inbetween two statewide Collaborative Quality InitiativesMOQC and MICMT (Michigan each practice over a 6- or 12-monthInstitute for Care Management and Transformation)and was developed to assist period do not meet the last criterion.oncology practices with improving patient care and outcomes through integration of If you would like to be part of theclinical oncology pharmacists in direct patient care. Clinical oncology pharmacists will Measures Committee or have anyprovide clinical care to high-risk oncology patients in oncology practices across the state questions about the measures or pastof Michigan. The program is beginning its pilot phase with the hiring of 3 clinical oncology measures, please contact us at www. pharmacists within MOQC practices across the State. Another 6 MOQC practices will be moqc.org. Value-basedeligible to participate beginning in 2021. The initiative provides financial support for the reimbursement measures and targetspharmacist salary, a value based reimbursement for participation, and clinical guidance are available by contacting theand outcome assessment. See our website and or contact Dr. Emily Mackler at Coordinating Center at 1.866. emackler@moqc.org for more information.GET-MOQC or emailing JenniferMOQCATASCO:SHININGALIGHTONGUIDELINE-CONCORDANTCAREGriggs at jengrigg@umich.edu orThe ASCO Quality Care Symposium took place virtually on October 9 and 10, 2020. Louise Bedard at lbedard@moqc.org.Emily Mackler, PharmD, presented the work by MOQC practices in improving their performance and concordance with guidelines for chemotherapy-induced nausea and vomiting (CINV) during the Rapid Abstract Session on the 10th. You have effectively decreased inappropriate use of low value antimetics from a baseline mean performance of 34% to a post-intervention performance of 19% (p0.05). Congratulations to all the MOQC practices on your great work! See link for full abstract: https://meetinglibrary.asco.org/record/192715/abstract. 5'